Forest Laboratories, Inc. (FRX) Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation
7/22/2013 9:41:18 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings, Ltd. (collectively, "Forest") announced today that they have entered into a settlement agreement with Amerigen Pharmaceuticals, Inc. and Amerigen Pharmaceuticals, Ltd. (collectively, "Amerigen") in patent infringement litigation brought by Forest in response to Amerigen's abbreviated new drug application (ANDA) seeking approval to market generic versions of Forest's BYSTOLIC® (nebivolol) tablets. This settlement agreement is in addition to the previously announced BYSTOLIC® patent infringement settlement agreements with Hetero Labs Ltd., Alkem Laboratories, Ltd., Indchemie Health Specialties Pvt. Ltd., Torrent Pharmaceuticals Ltd, and Glenmark Pharmaceuticals Ltd.
Help employers find you! Check out all the jobs and post your resume.
comments powered by